Investigating the role of AC in the outcome of patients with non-small-cell lung cancer (NSCLC) who have received anti-PD-1 or anti-PD-1-ligand (PD-L1) treatment, Nichetti et al. found no effect of AC on the progression-free survival (PFS) or overall survival (OS) [16]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.